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Methylenetetrahydrofolate reductaseBackground: Methotrexate is the most commonly used disease-modifying anti-rheumatic drug (DMARD)
and it is considered the first-line treatment in the management of rheumatoid arthritis (RA). MTX treat-
ment outcome regarding response to the drug and adverse effects in RA patients are not universal.
Therefore, it would be beneficial if we could predict the response of patients to MTX before starting
MTX treatment in order to determine the patient’s drug-treatment plan. Objectives: The present study
aimed to evaluate the impact of MTHFR A1298C SNP (rs1801131) on the clinical outcome of MTX treat-
ment as regards treatment efficacy and toxicity in a cohort of Egyptian rheumatoid arthritis patients.
Patients and methods: Fifty rheumatoid arthritis patients were included in the present study. Data about
patient related variables such as age and sex, disease related variables such as disease duration as well as
treatment related variables such as treatment duration, dose of MTX, its route of administration and con-
comitant use of other drugs (NSAIDs) were obtained. DAS28 was calculated to all patients to assess drug
response. MTHFR A1298C polymorphism was investigated using real time 50 nuclease allelic discrimina-
tion assay. Results:Multivariate regression analysis for factors predicting MTX drug response showed that
MTHFR A1298C SNP and MTX dose were the most significant independent predictors for MTX treatment
response (p = .016, OR = 39.113, 95% C.I = 1.970–776.558, p = .003, OR = 1.667, C.I = 1.184–2.348, respec-
tively). Considering clinicopathological variables; longer disease duration, positive anti-CCP, NSAIDs
users, higher MTX doses and longer treatment durations were significantly associated with non-
response to MTX. Regarding MTX drug toxicity, MTHFR 1298 CC genotype, MTX dose and concomitant
use of NSAIDs were significantly associated with MTX drug toxicity (MCp = .003, p = .031, p = .029, respec-
tively). Conclusion: Our study proved that MTHFR A1298C SNP can predict clinical outcome of MTX treat-
ment as regards treatment efficacy and toxicity in Egyptian rheumatoid arthritis patients.
 2018 Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Rheumatoid arthritis (RA) is a common systemic inflammatory
disorder characterized by symmetric arthritis and synovial inflam-mation leading to progressive joint erosion that end with joint
deformity.1 The prevalence of RA ranges from 0.5% to 1% world-
wide. The incidence varies based on gender, population and ethnic-
ity. It is estimated to be 30 cases per 100,000 people per year.2
The etiology of RA is unknown. Genetic susceptibility may pre-
dispose to RA and it can also be triggered by environmental factors
such as smoking and air pollutants.3
The synovial inflammation characteristic of RA involves multi-
ple immune cells which act together to form the observed synovial
hyperplasia and degradation of cartilage and bone.4,5
The management of RA depends mainly on the use of DMARDs.
These agents are commonly characterized by their ability to reduce
or reverse signs and symptoms and progression of joints damage.
So, DMARDs interfere with the entire disease process and these
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is the most commonly used DMARD and it is considered the first-
line treatment in the management of RA.7 Although MTX is one of
the best-tolerated DMARDs for the treatment of RA, major draw-
backs of MTX therapy are detected such as large inter-patient vari-
ability in clinical response and large spectrum of side effects.8
Factors influencing disease course and therapeutic outcome
include clinicopathological variables such as patient-related vari-
ables, disease-related variables and treatment-related variables
in addition to genetic factors such as genetic polymorphisms in
the key MTX pathway genes.9
The study of the associations between genetic variations such
as polymorphisms and drug efficacy and toxicity is known as
pharmacogenetics. Thus, pharmacogenetic studies can predict
the therapeutic outcomes of MTX and this in turn may help
clinicians to individualize appropriate treatment for each
patient.10
The MTHFR gene which is located on the short arm of
chromosome 1 (1p36.3), consists of 11 exons and 10 introns.11
This gene codes for a 77-kDa protein.12 MTHFR has a role in
conversion of 5, 10-methylenetetrahydrofolate into 5-methyl-
tetrahydrofolate (5 methyl-THF). 5 methyl-THF acts as a methyl
donor for remethylation of homocysteine to methionine. There
are several polymorphisms in MTHFR gene but only C677T
(rs1801133) and A1298C (rs1801131) polymorphisms affect
enzyme activity. So, they are considered the two most important
polymorphisms that may influence the therapeutic response to
MTX.13 The A1298C polymorphism is a missense mutation con-
sisting of A to C transition at base pair 1298 leading to substitu-
tion of a glutamate by alanine. This polymorphism results in
reduction of the enzyme activity, but to lesser extent than the
C677T polymorphism.142. Aim of the study
The present study aimed to evaluate the impact of MTHFR
A1298C SNP (rs1801131) on the clinical outcome of MTX treat-
ment as regards treatment efficacy and toxicity in a cohort of Egyp-
tian rheumatoid arthritis patients.3. Subjects and methods
3.1. Subjects
The study was conducted on fifty Egyptian patients who were
diagnosed as having RA based on the American College of Rheuma-
tology (ACR) 2012.
All patients received low-dose MTX for at least 3 months. Non-
steroidal anti-inflammatory drugs (NSAIDs) were allowed n the
first 8 weeks of the disease and all patients received folic acid sup-
plementation to prevent adverse effects induced by MTX. Any
patient received biopharmaceutical therapy or another DMARD
concomitantly during the 2-month period prior to enrollment in
the study was excluded. This study has been approved by the
Ethics Committee of Alexandria University and a written informed
consent was obtained from all participants.
Full history was taken from all participants, including patient
related variables such as age and sex, disease related variables such
as disease duration in addition to treatment related variables such
as treatment duration, dose of MTX, its route of administration as
well as concomitant use of other drugs such as NSAIDs.
Review of the patients’ medical records regarding their MTX
weekly dose (mg/week) and some laboratory investigations (RF,
anti-CCP).3.2. Methods
3.2.1. Clinical assessments
Patients’ clinical and demographic data were collected at the
single study visit. Clinical efficacy was assessed using the disease
activity score in 28 joints (DAS 28). The occurrence of side effects
was retrospectively recorded at the time of the study visit. MTX
related side effects were classified as (1) gastrointestinal complaint
such as anorexia, nausea, vomiting and diarrhea. (2) Mucocuta-
neous complaint such as alopecia, rashes and oral ulcers. (3) Cen-
tral nervous system toxicity such as insomnia, headache and
dizziness. (4) Pulmonary toxicity such as cough and pneumonitis.
(5) Hepatotoxicity; elevation of serum transaminases above the
upper range of normal. (6) Bone marrow toxicity such as mega-
loblastic anaemia, leucopenia, thrombocytopenia and pancytope-
nia. (7) Renal toxicity; elevation of creatinine levels above the
upper range of normal.
3.2.2. Routine laboratory investigations
Complete blood count, liver function, renal function and CRP
were measured on the day of the study visit using standard labora-
tory methods.
3.2.3. Molecular studies
 Genomic DNA was extracted from EDTA whole blood samples
using QIAamp DNA blood mini Kit 50 (Qiagen, CA, USA, cat.
no. 51104). The concentration and purity of extracted DNA
was assessed using a nanodrop 2000 spectrophotometer and
then stored at 20 C till genotyping.
 The 1298A > C polymorphism (rs1801131) was detected by 50
nuclease allele discrimination assay using real-time polymerase
chain reaction (PCR). Amplification done according to the fol-
lowing steps: 10 ml of TaqMan universal PCR Master Mix (2X)
was added followed by 0.5 ml of Primer/probe mix (40X). Then
1 ml of extracted DNA (DNA was diluted in nuclease-free water
in order to deliver 1–20 ng per well) and sterile water were
added to complete a total volume of 20 ml. Rotorgene Q Real
time PCR system was employed to obtain specific sequences
using the following thermal profile: holding at 95 C for 10
min followed by 40 cycles of denaturation (92 C for 15 s) and
annealing/extension (60 C for 1 min).
3.2.4. Statistical analysis of the data
Data were fed to the computer and analyzed using IBM SPSS
software package version 20.0 (Armonk, NY: IBM Corp). Qualitative
data were described using number and percent. Quantitative data
were described using range, mean, standard deviation and median.
Significance of the obtained results was judged at the 5% level. Chi-
square test or Fisher’s Exact and Monte Carlo correction was used
to compare between different groups. For normally quantitative
variables, to compare between two studied groups Student t-test
was applied. Odd ratio was used to calculate the ratio of the odds
and 95% Confidence Interval of an event occurring in one risk group
to the odds of it occurring in the non-risk group.4. Results
A total of 50 patients with RA were enrolled to the study (43
females and 7 males) with a mean age of 43.12 ± 9.66 years and
a mean disease duration of 4.52 ± 3.82 years. Considering MTX
treatment, the mean treatment duration was 3.66 ± 3.25 years
with a mean MTX dose of 17.08 ± 6.84 mg/week. Furthermore,
46 patients (92%) administered MTX by IM administration route
and 4 (8%) by PO administration route. The mean DAS28 was
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are considered responders while 33 patients (66%) have DAS28
>3.2 and they are considered non-responders. Regarding MTX
adverse effects, 34% of patients developed drug toxicity during
treatment period.
Concerning disease-related variables, our results demonstrated
a statistically significant association between disease duration and
MTX drug response (p = .028). Also patients with positive anti-CCP
were significantly associated with non-response to MTX
(FEp = .008). Considering treatment related variables, our results
revealed a significant association between concomitant use of
NSAIDs, higher MTX doses and MTX non response (p = .033,
p < .001, respectively). In addition, we observed that longer
treatment durations were significantly associated with MTX non-
response (p = .027).
The distribution ofMTHFR A1298C genotypes were 24 AA (48%),
20 AC (40%) and 6 CC (12%). The major allele was A and the minor
allele was C. The genotype frequency of MTHFR A1298C was in
Hardy-Weinberg equilibrium (p = .567).
A statistically significant association was found betweenMTHFR
A1298C genotype and MTX drug response (MCp = .047); 50% of the
patients with AA genotype showed good clinical response
compared to 25% and 00% with AC and CC, respectively. It wasTable 1








Responder 12 50.0 5
Non responder 12 50.0 15
v2: Chi square test.
MC: Monte Carlo for Chi square test.






















Fig. 1. Relation between MTHFR A1298Cconcluded that AA genotype was associated with better drug
response. Table 1, Fig. 1
Binary logestic regression study proved that MTHFR A1298C
genotype and MTX dose were the most significant independent
predictors for MTX treatment response (p = .016, OR = 39.113,
95% C.I = 1.970–776.558, p = .003, OR = 1.667, C.I = 1.184–2.348,
respectively) Table 2.
As regards MTX drug toxicity, a statistically significant relation
was observed between the dose of MTX and drug toxicity
(p = .031). Moreover, concomitant use of NSAIDs was significantly
associated with MTX drug toxicity (p = .029).
Regarding the relation between MTHFR A1298C SNP and MTX
drug toxicity, our results showed a significant association between
MTHFR 1298 CC genotype and MTX drug toxicity (MCp = .003)
Table 3, Fig. 2.
5. Discussion
MTX represents an interesting target for pharmacogenetic
studies. This helps identification of response predictors to achieve
maximal response with minimal toxicity.15
The present study investigated the relation between MTHFR








genotype and MTX drug response.
Table 2
Binary logistic regression for the parameters that affecting MTX drug response.
B S.E. Sig. OR 95% C.I
L.L U.L
Dose of MTX 0.511 0.175 0.003* 1.667* 1.184 2.348
Anti CCP 2.177 1.309 0.096 8.823 0.678 114.845
Disease duration (years) 0.154 0.529 0.771 0.857 0.304 2.417
NSAIDs 1.117 1.693 0.510 0.327 0.012 9.045
Treatment duration (years) 0.194 0.582 0.739 1.214 0.388 3.799
MTHFR A1298C (AC + CC genotypes) 3.666 1.525 0.016* 39.113* 1.970 776.558
Table 3
Relation between MTHFR A1298C genotype and MTX drug toxicity.







No. % No. % No. %
Toxicity
No 14 58.3 18 90.0 1 16.7 12.040* .003*
Yes 10 41.7 2 10.0 5 83.3
v2: Chi square test.
MC: Monte Carlo for Chi square test.
* Statistically significant at p  .05.
Fig. 2. Relation between MTHFR A1298C genotype and MTX drug toxicity.
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non-response (MCp = .047). Carriers of C allele are significantly
associated with non-response to MTX than non carriers
(p = .008). This may be attributed to reduction of MTHFR activity
leading to reduced 5-MTHF and other folate cofactors levels which
in turn leads to decreased adenosine release that partially explain
MTX non-response.16,17
Similar results were detected by Kato et al.18 andWessels et al.19
They observed that MTHFR 1298AA was associated with good
response relative to 1298C allele carriers. In addition, Ghodke-
Puranik et al.20 evaluated the influence of 12 genetic polymor-phisms in folate pathway genes in Indian rheumatoid arthritis
patients receiving MTX. It was concluded that patients carrying
at least one MTHFR 1298A allele (AA-AC) were more likely to have
better MTX efficacy relative to those with MTHFR 1298 CC.
In contrast to our results, Kurzawski et al.21 suggested that
MTHFR 1298C alleles may be associated with an increased rate of
RA remission in patients treated with MTX receiving high doses
of folic acid supplementation. These results were explained by
down regulation of 5-methyl-THF synthesis through MTHFR and
subsequently reduced methionine production from homocysteine
and 5-methyl-THF through methionine synthase and decreased
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main donor of methyl group in numerous biochemical pathways
and reactions of DNA methylation. The limited availability of S-
adenosylmethionine may affect expression of many genes, being
a postulated mechanism of immunosuppressive properties of
MTX.21
Similarly, Urano et al.22 examine whether there was a correla-
tion between MTHFR gene and the efficacy or toxicity of MTX in
the treatment of RA. They concluded that improvement in ESR
and CRP was significantly associated with increasing numbers of
1298C alleles. This was attributed to exertion of MTX efficacy
through inhibition of folate metabolism. So, the reduction in the
activity of a key enzyme in folate metabolism is likely to enhance
the effects of MTX.
Taraborelli et al.23 conducted their study to investigate the role
of genetic screening of MTHFR polymorphisms (C677T, A1298C) in
planning the treatment of rheumatoid patients. Against our results,
they did not find any significant association between MTHFR
A1298C genotype/allele and MTX response.
Also, Kumagai et al.24 and Bohanec et al.25 investigated the
influence of common SNPs in genes of the folate metabolic path-
way on the efficacy and toxicity of MTX treatment in a group of
RA patients. Regarding treatment response, they did not find any
significant association between MTHFR A1298C genotype and
MTX response.
Moreover, the present study investigated the relation between
multiple clinicopathological variables and MTX drug response.
Regarding disease related variables, longer disease duration and
positive anti-CCP were significantly associated with non response
to MTX (p = .028, FEp = .008, respectively).
In agreement with our results, Lee et al.26 studied the relation
between three candidate alleles in the ATIC, ITPA and MTHFR genes
and DAS28-CRP as a marker of disease activity. It was concluded
that disease duration and anti-CCP were significantly associated
with MTX drug response (p = .002, p = .01, respectively).
In contrast to our results, Iqpal et al.27 investigated the associa-
tion between SNPs in MTHFR gene (C677T and A1298C) with
response to MTX therapy in Pakistani RA patients. It was proved
that disease duration was not significantly associated with MTX
treatment response (p = .53).
Regarding treatment related variables, the present study con-
cluded that NSAIDs users, higher MTX doses and longer treatment
durations were significantly associated with non-response to MTX
(p = .033, p < .001, p = .027, respectively).
In concordance with our results, Lima et al.9 studied the role of
MTHFR C677T and ATIC T675C polymorphisms and clinicopatho-
logical variables in clinical response to MTX in RA patients. It
was found that MTX dose and concomitant use of NSAIDs were sig-
nificantly associated with MTX drug response. However, no signif-
icant relation was detected between treatment duration and MTX
response (p = .204).
Contrary to our results, Świerkot et al.28 evaluated the effect of
gene polymorphisms on the efficacy of therapy and side effects in
RA patients treated with MTX. It was observed that MTX dose and
concomitant use of NSAIDs were not associated with MTX drug
response (p = 1, p = .76, respectively).
In addition, our study revealed also a significant association
between MTHFR 1298 CC genotype and MTX drug toxicity (MCp
= .003). This could be explained by low drug response with MTHFR
1298CC genotype. Therefore those with CC genotype need higher
doses of MTX to achieve response which lead to exposure to more
side effects.
In accordance to our results, Choe et al.29 observed that the pro-
portion of rheumatoid patients with MTHFR 1298CC genotype who
experienced at least one drug toxicity was significantly greaterthan the proportion of patients with 1298AA. However, Davis
et al.30 and Dervieux et al.31 observed that MTHFR 1298AC/CC
genotypes were associated with an increased risk of toxicity.
On the other hand, Cáliz et al.7 assessed the involvement of the
C677T and A1298C polymorphisms in the MTHFR gene in the tox-
icity of MTX in a group of RA patients. As regards MTHFR A1298C,
they observed that MTHFR A1298C polymorphism was not signifi-
cantly associated with increased MTX toxicity (p = .761).
Similarly, Taraborelli et al.23 concluded that MTHFR A1298C
polymorphism was not significantly associated with MTX drug
toxicity.
As regards the relation between clinicopathological variables
and MTX drug toxicity, the present study detected a significant
association between concomitant use of NSAIDs, MTX dose and
MTX drug toxicity (p = .029, p = .031, respectively).
Jenko et al.32 investigated predictors of MTX induced adverse
events that may lead to treatment discontinuation. They observed
a significant association between dose of MTX and drug toxicity
(p = .03).
On the other hand, Lima et al.33 found no association between
co-administration of NSAIDs and MTX drug toxicity (p = .053).
The discrepancy between our results and previous studies may
be attributed to different ethnic populations, larger sample size
compared to our study, the prescription of folate supplementation,
different methods of MTX drug response evaluation and different
techniques used for SNPs genotyping.
6. Conclusion
Our study found that MTHFR A1298C SNP (rs1801131) can pre-
dict clinical outcome of MTX treatment as regards treatment effi-
cacy and toxicity in Egyptian rheumatoid arthritis patients. Thus
pharmacogenetics can help clinicians to take appropriate treat-
ment decisions.
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